Global Perspectives
As part of a global ecosystem, Genetron collaborates with two of the world’s leading cancer research institutions, Duke University and Johns Hopkins University. These partnerships ensure that every innovation and service remains aligned with the latest advancements in cancer research. In China, Genetron operates central laboratories in Beijing, Wuxi, and Guangzhou, supported by manufacturing facilities certified with ISO13485:2016 and ISO9001:2015. In addition, Genetron has established a global network through partnerships with local distributors and collaborative laboratories across various countries, continuously expanding its reach in the international market.
Laboratory in Indonesia
Genetron Indonesia represents the fifth central laboratory established globally and marks a strategic step in expanding its presence in Southeast Asia. This initiative is realized through a joint venture with YesStar Healthcare to deliver precision oncology services in Indonesia. With the ambition to become the largest precision oncology laboratory in Indonesia by Q1 2026, Genetron Indonesia provides comprehensive services, including:
- Cancer screening
- Diagnosis and monitoring
- NIPT and PGT services
End-to-End Cancer Care Solutions
Genetron Indonesia delivers comprehensive solutions that cover the full spectrum of cancer care, including:
- Early cancer screening
- Minimal Residual Disease (MRD) detection
- More precise therapy selection
These services are designed for a wide range of patient segments:
- High-risk individuals
- Early to intermediate-stage post-operative patients
- Patients with advanced solid tumors
Key products include:
- HCCscan and HCCscreen
- Genetron MRD and Seq-MRD
- Lung Basic
- Onco Sonar and Onco PanScan
Strategic Vision
Genetron Indonesia aims to become a center of excellence in molecular diagnostics, not only in Indonesia but across Southeast Asia. To achieve this vision, the company implements a phased development strategy:
Phase 1: Foundation & Credibility
- Ensuring compliance with national and international regulations, including the Ministry of Health and ISO 15189
- Building credibility through partnerships with government institutions and leading hospitals
- Securing early revenue through strategic collaborations
Phase 2: Scale & Profitability
- Achieving profitability with a sustainable business model
- Expanding access to high-quality diagnostic services
- Integrating screening services into the national healthcare financing system
